Cytek Biosciences (CTKB) Free Cash Flow (2020 - 2026)

Cytek Biosciences' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$4.9 million for Q1 2026.

• Quarterly Free Cash Flow fell 1266.02% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.4 million (down 143.63% YoY) and the FY2025 annual result came in at -$4.8 million, down 119.11% from the prior year.
• Free Cash Flow was -$4.9 million for Q1 2026 at Cytek Biosciences, down from $2.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $14.7 million in Q3 2024 and bottomed at -$11.3 million in Q2 2022.
• A 5-year average of -$73823.5 and a median of -$337000.0 in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 3844.81% — and 2026, when it tumbled 1266.02%.
• Cytek Biosciences' Free Cash Flow stood at -$337000.0 in 2022, then soared by 3844.81% to $12.6 million in 2023, then tumbled by 84.79% to $1.9 million in 2024, then grew by 13.76% to $2.2 million in 2025, then plunged by 324.64% to -$4.9 million in 2026.
• Business Quant data shows CTKB's Free Cash Flow at -$4.9 million in Q1 2026, $2.2 million in Q4 2025, and -$6.9 million in Q3 2025.